Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: embryonic stem cell therapies - ES Cell International

Drug Profile

Research programme: embryonic stem cell therapies - ES Cell International

Alternative Names: ESI-014; ESI-017; ESI-035; ESI-049; ESI-051; ESI-053

Latest Information Update: 05 Jul 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator
  • Developer ES Cell International; Lineage Cell Therapeutics; University of California at Irvine
  • Class Antihyperglycaemics; Cardiovascular therapies; Neural stem cell therapies; Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Diabetes mellitus; Heart failure; Huntington's disease

Most Recent Events

  • 31 Mar 2021 ES Cell International in-licenses human embryonic stem cell lines from AgeX Therapeutics before March 2021
  • 31 Mar 2021 ES Cell International has patent protection for embryonic stem cell therapeutics in USA, Australia, Israel, UK, Singapore, Japan
  • 31 Mar 2021 ES Cell International has patents pending for embryonic stem cell therapies in USA and Europe
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top